SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

iberdomide

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating6/10
Trial phase
Filed / PDUFA pending (NDA under FDA review; pivotal program completed)
Time to market
FDA decision due August 17, 2026 (~2 weeks away); if approved, commercial launch would follow later in 2026.
Why 6/10
The single next hard, dated catalyst is the FDA PDUFA decision on August 17, 2026 for the iberdomide + daratumumab + dexamethasone NDA in relapsed/refractory multiple myeloma, a binary approval/CRL event roughly two weeks away. Score is 6 (not 8+) because the catalyst is imminent but iberdomide is one program inside a ~$129B diversified company, so even a clean approval or a CRL moves BMY only a few percent, not a make-or-break swing.
Actionable Insight NEUTRAL

Mark August 17, 2026 on the calendar: the FDA target action date for iberdomide in relapsed/refractory multiple myeloma. An approval would give BMY a potential first-in-class oral CELMoD (next-gen successor to its Revlimid/Pomalyst franchise) and is likely a modestly positive headline; a CRL or review extension is the bigger downside risk to watch. Because iberdomide is a small slice of a mega-cap with a rich pipeline (mezigdomide PDUFA already cited for May 2027), treat the decision as a franchise-confidence signal, not a standalone trade.

Price Chart

Loading chart...

Executive Summary

Iberdomide is Bristol Myers Squibb's next-generation oral CELMoD for multiple myeloma, filed with the FDA as a triplet with daratumumab and dexamethasone for relapsed/refractory disease; the FDA accepted the NDA and set a PDUFA date of August 17, 2026. It is a strategic franchise asset for BMY as its legacy Revlimid (-49% YoY in Q2 2026) and Pomalyst/Imnovid (-71%) sales collapse under generic erosion, and BMY's own Q2 2026 earnings analysis flags the iberdomide PDUFA as a near-term derisking catalyst. The counterweight: iberdomide is one program inside a ~$129B-market-cap diversified pharma, faces a crowded relapsed-myeloma field, and historical BMY PDUFA reactions in the local catalyst record were modest (roughly +3% and -1% one-day moves).

How It Works

Iberdomide is an oral pill in the same family as BMY's older blockbuster myeloma drugs Revlimid and Pomalyst, but engineered to be more potent. It hijacks the cell's protein-disposal system so that key proteins inside myeloma cells and immune cells get destroyed, which both kills tumor cells and reshapes the immune system to attack the cancer. The application under FDA review pairs it with daratumumab (a targeted antibody) plus dexamethasone (a steroid) for patients whose multiple myeloma has returned or stopped responding to treatment.

Trial Status

The FDA accepted the New Drug Application for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma (NDA submission dated 2026-02-17) and assigned a PDUFA target action date of August 17, 2026. No FDA action (approval or CRL) outcome is stored yet.

The Two-Sided Case

▲ Bull Case4
FDA accepted the NDA for iberdomide + daratumumab + dexamethasone and assigned a PDUFA date of August 17, 2026, a hard, dated, near-term binary catalyst (FDA catalyst records / event ledger, stored 2026-04-30).
BMY's Q2 2026 earnings analysis explicitly lists iberdomide as an upcoming PDUFA catalyst (Aug 17, 2026) that 'could further derisk the long-term growth story,' alongside a strong quarter that beat EPS consensus by ~27.7% and raised full-year guidance (8-K filing analysis, filed 2026-07-30).
Iberdomide extends the franchise that produced Revlimid/Pomalyst, the class works, and iberdomide is positioned as the more potent next generation; the 8-K report names iberdomide and mezigdomide as the CELMoD pipeline.
BMY shares trade near the analyst mean price target of $63.96 (current $65.31, implied upside ~0.3%), with 14 of 35 ratings Buy/Strong Buy, so a clean approval would reinforce a consensus that already leans positive.
▼ Bear Case4
The same oral-myeloma class is eroding fast: Revlimid sales fell ~49% YoY and Pomalyst/Imnovid ~71% in Q2 2026 on generic competition, evidence that oral myeloma drugs face rapid pricing/competition pressure once the patent window opens (8-K filing analysis).
Relapsed/refractory multiple myeloma is a crowded field; iberdomide must differentiate against newer mechanisms, and no approval outcome is stored yet, so a CRL or review delay at the August 17, 2026 PDUFA is a real (if not priced) downside headline.
Iberdomide is a modest slice of a ~$129B company: historical BMY PDUFA/priority-review reactions in the local catalyst record were small (e.g., +3.12% and -0.74% 1-day moves; the iberdomide NDA-submission event moved BMY -1.66% 1-day), so even the binary itself has limited upside for the stock.
Net debt of ~$31.7B and rising operating-expense guidance (~$16.5B) mean BMY is funding a big pipeline; a franchise asset that disappoints commercially adds to margin pressure (8-K filing analysis).

Upcoming Catalysts

  • FDA PDUFA decision for iberdomide + daratumumab + dexamethasone in relapsed/refractory multiple myeloma, August 17, 2026 (stored event, severity critical).
  • Post-decision commentary at BMY's next quarterly earnings; a second CELMoD PDUFA (mezigdomide) is already flagged for May 13, 2027 per the Q2 2026 earnings analysis, keeping the franchise in focus.
  • Any FDA action rows (approval/CRL) that appear in FDA datasets after the PDUFA date.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 6

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov6 sec.gov